Cas:96-62-8 3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide manufacturer & supplier

We serve Chemical Name:3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide CAS:96-62-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide

Chemical Name:3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide
CAS.NO:96-62-8
Synonyms:Di-m-nitrobenzenesulfonylethylenediamine;N,N’-Di(3-nitrobenzenesulfonyl)ethylenediamine;DINSED
Molecular Formula:C14H14N4O8S2
Molecular Weight:430.41300
HS Code:2935009090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:659.9ºC at 760mmHg
Density:1.563g/cm3
Index of Refraction:1.628
PSA:200.74000
Exact Mass:430.02500
LogP:4.74960

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Di-m-nitrobenzenesulfonylethylenediamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DINSED physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DINSED Use and application,Di-m-nitrobenzenesulfonylethylenediamine technical grade,usp/ep/jp grade.


Related News: A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide manufacturer API and raw material are often confused due to the similar usage of the two terms. 3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide supplier A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide vendor A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 3-nitro-N-[2-[(3-nitrophenyl)sulfonylamino]ethyl]benzenesulfonamide factory In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase.